Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 20/20 | 0.78 |
| ▸ | PPIB | P23284 | 8/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | PPIF | P30405 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.70 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183892 | 0.90 | PPIA (0.78) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL12994808 | 0.90 | PPIA (0.84) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL12994814 | 0.90 | PPIA (0.84) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15383383 | 0.89 | PPIA (0.91) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183862 | 0.89 | PPIA (0.91) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL12994801 | 0.88 | PPIA (0.90) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15383384 | 0.88 | PPIA (0.90) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL11957327 | 0.88 | PPIA (0.82) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15383382 | 0.88 | PPIA (0.90) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183894 | 0.87 | PPIA (0.79) | PPIAPPIBCYP3A4CYP2C9PPIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196749-A1 | Cyclosporin Derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196749-A1 | Cyclosporin Derivatives | TSLP, FKBP14, CHP1 | PPIA 59/4885PPIB 67/4885CYP3A4 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.